Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
We have shown previously that the camptothecin analogue topotecan (TPT), a topoisomerase I (Top 1) poison, inhibits hypoxia-inducible factor 1 (HIF-1) transcriptional activity and HIF-1α protein accumulation in hypoxia-treated U251 human glioma cells. In this article, we demonstrate that TPT does not affect HIF-1α protein half-life or mRNA accumulation but inhibits its translation. In addition, we demonstrate that Top 1 is required for the inhibition of HIF-1α protein accumulation by TPT as shown by experiments performed using camptothecin-resistant cell lines with known Top 1 alterations. Experiments performed with aphidicolin indicated that TPT inhibited HIF-1 protein accumulation in the absence of DNA replication. DNA-damaging agents, such as ionizing radiation and doxorubicin, did not affect HIF-1α protein accumulation. Ongoing transcription was essential for the inhibition of HIF-1α protein accumulation by TPT. Our results demonstrate the existence of a novel pathway connecting Top 1-dependent signaling events and the regulation of HIF-1α protein expression and function. In addition, our findings dissociate the cytotoxic activity of TPT from the inhibition of the HIF-1 pathway and raise the possibility of novel clinical applications of TPT aimed at targeting HIF-1-dependent responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inhibition of TOPI by CPT also suppresses HIF-1 protein accumulation, downregulating transcription of HIF-1-regulated genes involved in angiogenesis, glucose metabolism, immortalization, immune evasion, invasion and metastasis, drug resistance, and cancer stem cell (CSC) maintenance and proliferation29,30.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [30]
In the citing paper
“Camptothecins (CPTs, 3) analogues, which have topoisomerase I (Top I) inhibitory activity, can inhibit HIF-1α protein accumulation in hypoxic U251 human glioma cells.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [48]
In the citing paper
“In hypoxia-exposed U251 human glioma cells, topotecan does not affect HIF1A mRNA abundance but instead reduces the rate of HIF-1α protein synthesis, independently of the PI3K–Akt–mTOR pathway [314].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [314]
In the citing paper
“Importantly, topotecan does not inhibit global protein synthesis or the accumulation of unrelated proteins, arguing against nonspecific translational toxicity and supporting a selective mechanism of HIF-α regulation.”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [314]
In the citing paper
“Our group has recently shown that topotecan, a topoisomerase I poison, inhibits HIF-1a protein accumulation independently of DNA replication-mediated DNA damage, suggesting a distinct mechanism of action from the cytotoxic effects (35).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [35]
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · cited 1×
“The expression and activity of the HIF- subunit are regulated uniquely by the intracellular oxygen concentration (1, 2).”
BackgroundJaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
(1999) · PubMed · Cited by 2,204
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
(2000) · PubMed · Cited by 1,445
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Cited by
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Self-citationTopoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Self-citationHIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Ziello, J. E., Jovin, I. S., & Huang, Y. (2007) · PubMed Central · Cited by 894
The genetic basis of kidney cancer: a metabolic disease
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.47 · Cited by 744
Metadata
- Authors
- Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- 1Developmental Therapeutics Program,
- Venue
- Cancer Research
- Published
- 2004-02-15
- Volume
- 64
- Issue
- 4
- Pages
- 1475-1482
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2057366549
- Cited by
- 301
- References
- 49
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 9 · 2022: 5 · 2021: 13 · 2020: 13 · 2019: 14 · 2018: 8 · 2017: 12 · 2016: 12 · 2015: 19 · 2014: 12 · 2013: 11 · 2012: 18
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01co12400-79-0-22)
- National Cancer Institute (N01CO12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- topotecan, topoisomerase I, HIF-1, HIF-1α, transcriptional regulation, camptothecin resistance, U251 cells, ionizing radiation, doxorubicin
- MeSH terms
- Cysteine Endopeptidases, DNA Damage, DNA Replication, DNA Topoisomerases, Type I, Dose-Response Relationship, Drug, Humans, Multienzyme Complexes, Protein Kinases, Proto-Oncogene Proteins, RNA, Messenger, Transcription Factors, Transcription, Genetic, Protein Biosynthesis, Protein Serine-Threonine Kinases, Topotecan, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Proteasome Endopeptidase Complex, Proto-Oncogene Proteins c-akt, Hypoxia-Inducible Factor 1, alpha Subunit, TOR Serine-Threonine Kinases, Topoisomerase I Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1. https://app.cochat.ai/papers/10.1158/0008-5472.can-03-3139
- The paper
- Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004). Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1. Cancer Research. https://doi.org/10.1158/0008-5472.can-03-3139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.